Toll-like Receptor (TLR)

Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. They are single, membrane-spanning, non-catalytic receptors usually expressed in sentinel cells such as macrophages and dendritic cells, that recognize structurally conserved molecules derived from microbes. Once these microbes have breached physical barriers such as the skin or intestinal tract mucosa, they are recognized by TLRs, which activate immune cell responses. The TLRs include TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13. Toll-Like Receptors (TLRs) play a critical role in the early innate immune response to invading pathogens by sensing microorganism and are involved in sensing endogenous danger signals. TLRs are evolutionarily conserved receptors are homologues of the Drosophila Toll protein, discovered to be important for defense against microbial infection. TLRs recognize highly conserved structural motifs known as pathogen-associated microbial patterns (PAMPs), which are exclusively expressed by microbial pathogens.

(R)-Hydroxychloroquine

((R)-HCQ) Cat. No.: HY-B1370B

(R)-Hydroxychloroquine is the enantiomer of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial drug which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(S)-Hydroxychloroquine

((S)-HCQ) Cat. No.: HY-B1370A

(S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine. Hydroxychloroquine, a synthetic antimalarial drug, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

1V209

(TLR7 agonist T7) Cat. No.: HY-115400

1V209 (TLR7 agonist T7) is a **Toll-like receptor 7 (TLR7)** agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AN-3485

Cat. No.: HY-18325

AN-3485 is a benzoxaborole analog, **Toll-Like Receptor(TLR)** inhibitor with IC_{50} values ranging from 18 to 580 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

Atractylenolide I

Cat. No.: HY-N0201

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bropirimine

Cat. No.: HY-W008634

Bropirimine is a synthetic agonist for toll-like receptor 7 **(TLR7)**. Bropirimine inhibits differentiation of osteoclast precursor cells into osteoclasts via TLR7-mediated production of IFN-β.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

C29

Cat. No.: HY-100461

C29 is a **Toll-like receptor 2 (TLR2)** inhibitor. C29 blocks hTLR2/1 and hTLR2/6 signaling with IC_{50}s of 19.7 and 37.6 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Chitohexaose hexahydrochloride

Cat. No.: HY-N7697C

Chitohexaose hexahydrochloride is a chitosan oligosaccharide with anti-inflammatory effect. Chitohexaose hexahydrochloride binds to the active sites of **TLR4** and inhibits LPS induced inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Chloroquine

Cat. No.: HY-17589A

Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Chloroquine D5

Cat. No.: HY-17589AS

Chloroquine D5 is deuterium labeled Chloroquine. Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chloroquine dihydrochloride

Cat. No.: HY-17589B

Chloroquine dihydrochloride is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Chloroquine phosphate

Cat. No.: HY-17589

Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

CL075

(3M002)

Cat. No.: HY-117066

CL075 (3M002) is a selective **TLR8** agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

CU-CPT-8m

(TLR8-specific antagonist)

Cat. No.: HY-112050

CU-CPT-8m is a specific **TLR8** antagonist, with an IC_{50} of 67 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CU-CPT-9a

Cat. No.: HY-112667

CU-CPT-9a is a specific **TLR8** antagonist, with an IC_{50} of 0.5 nM.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CU-CPT17e

Cat. No.: HY-101929

CU-CPT17e is a potent multi-**Toll-like receptor** (**TLR**) agonist that activates **TLR3**, **TLR8**, and **TLR9**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CU-CPT22

Cat. No.: HY-108471

CU-CPT22 is a potent protein complex of **toll-like receptor 1 and 2 (TLR1/2)** inhibitor, and competes with the synthetic triacylated lipoprotein (Pam_3CSK_4) binding to TLR1/2 with a K_i of 0.41 μM. CU-CPT22 blocks Pam_3CSK_4-induced TLR1/2 activation with an IC_{50} of 0.58 μM.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

CU-CPT9b

Cat. No.: HY-112051

CU-CPT9b is a specific **TLR8** antagonist, with an IC_{50} of 0.7 nM. CU-CPT9b shows high binding affinity towards TLR8 with a K_d of 21 nM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CU-T12-9

Cat. No.: HY-110353

CU-T12-9 is a specific **TLR1/2** agonist with EC_{50} of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Desethyl chloroquine

Cat. No.: HY-135811

Desethyl chloroquine is a major desethyl metabolite of Chloroquine. Chloroquine diphosphate is an inhibitor of **autophagy** and **toll-like receptors (TLRs)**. Desethyl chloroquine possesses antiplasmodic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desethyl chloroquine diphosphate

Cat. No.: HY-135811A

Desethyl chloroquine diphosphate is a major desethyl metabolite of Chloroquine. Chloroquine diphosphate is an inhibitor of **autophagy** and **toll-like receptors (TLRs)**. Desethyl chloroquine diphosphate possesses antiplasmodic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

DSR-6434

Cat. No.: HY-110120

DSR-6434 is a potent and selective **Toll-like receptor 7 (TLR7)** agonist, with **EC_{50}**s of 7.2 nM and 4.6 nM for human and mice **TLR7**, respectively. DSR-6434 has a strong antitumor effect.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FSL-1 TFA

Cat. No.: HY-P2036A

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (**TLR2/6**) agonist, enhances resistance to experimental HSV-2 infection. FSL-1 TFA induces **MMP-9** production through **TLR2** and **NF-κB/AP-1** signaling pathways in monocytic THP-1 cells.

Purity: 99.58%
Clinical Data: No Development Reported
Size: 100 μg

Gardiquimod diTFA

Cat. No.: HY-103697A

Gardiquimod diTFA, an imidazoquinoline analog, is a **TLR7/8** agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10μM.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2245035

Cat. No.: HY-118250

GSK2245035 is a highly potent and selective intranasal **Toll-Like receptor 7 (TLR7)** agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has **pEC_{50}**s of 9.3 and 6.5 for IFNα and TFNα.



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hydroxychloroquine

Cat. No.: HY-W031727

Hydroxychloroquine is a synthetic **antimalarial** agent which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling. Hydroxychloroquine is efficiently inhibits **SARS-CoV-2** infection in vitro.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydroxychloroquine sulfate

(HCQ sulfate)

Cat. No.: HY-B1370

Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic **antimalarial** agent which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling. Hydroxychloroquine sulfate is efficiently inhibits **SARS-CoV-2** infection in vitro.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

IAXO-102

Cat. No.: HY-125171

IAXO-102 is a **TLR4** antagonist which negatively regulates TLR4 signalling. It inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Imiquimod

(R 837)

Cat. No.: HY-B0180

Imiquimod (R 837) is a selective **toll like receptor 7 (TLR7)** agonist acting as an immune response modifier. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID 19.



Purity: 99.96%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Imiquimod hydrochloride

(R 837 hydrochloride)

Cat. No.: HY-B0180A

Imiquimod hydrochloride (R 837 hydrochloride) is a selective **toll like receptor 7 (TLR7)** agonist acting as an immune response modifier. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo.



Purity: 99.77%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Imiquimod maleate

(R 837 maleate)

Cat. No.: HY-B0180B

Imiquimod maleate (R 837 maleate) is a selective **toll like receptor 7 (TLR7)** agonist acting as an immune response modifier. Imiquimod maleate exhibits antiviral and antitumor effects in vivo.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Isofraxidin

Cat. No.: HY-N0774

Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits **MMP-7** expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of **ERK1/2** in hepatoma cells.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

LHC-165

Cat. No.: HY-111786

LHC-165 is a **TLR7** agonist. Has potential to treat solid tumors.



Purity: 98.17%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 50 mg

Loxoribine

(7-Allyl-8-oxoguanosine; RWJ 21757)

Cat. No.: HY-108472

Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective **Toll-like receptor (TLR) 7** agonist.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MD2-IN-1

Cat. No.: HY-103483

MD2-IN-1 is an inhibitor of **Myeloid differentiation protein 2** (**MD2**) with a **KD** of 189 μM for the recombinant human MD2 (**rhMD2**).



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MD2-TLR4-IN-1

Cat. No.: HY-128598

MD2-TLR4-IN-1 (compound 22m) is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with...



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMG-11

Cat. No.: HY-112146

MMG-11 is a potent and selective human **TLR2** antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC_{50}s of 1.7 μM for Pam_3CSK_4-induced hTLR2/1 and 5.7 μM for Pam_2CSK_4-induced hTLR2/6 responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

MMG-11 quarterhydrate

Cat. No.: HY-112146A

MMG-11 quarterhydrate is a potent and selective human **TLR2** antagonist with low cytotoxicity. MMG-11 quarterhydrate inhibits both TLR2/1 and TLR2/6 signaling with IC_{50}s of 1.7 μM for Pam_3CSK_4-induced hTLR2/1 and 5.7 μM for Pam_2CSK_4-induced hTLR2/6 responses.



1/4 H_2O

Purity: >97.0%
Clinical Data: No Development Reported
Size: 10 mg

Motolimod

(VTX-2337; VTX-378)

Cat. No.: HY-13773

Motolimod (VTX-2337;VTX-378) is a selective **Toll-like receptor 8 (TLR8)** agonist, with an EC_{50} of approximately 100 nM.



Purity: 98.58%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Neoseptin 3

Cat. No.: HY-U00435

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (**mTLR4/MD-2**) agonist with an EC_{50} of 18.5 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Okanin

Cat. No.: HY-N6673

Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the **TLR4/NF-κB** signaling pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pam3CSK4

(Pam3Cys-Ser-(Lys)4)

Cat. No.: HY-P1180

Pam3CSK4 is a toll-like receptor 1/2 (**TLR1/2**) agonist with an EC_{50} of 0.47 ng/mL for human TLR1/2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Pam3CSK4 TFA

(Pam3Cys-Ser-(Lys)4 TFA)

Cat. No.: HY-P1180A

Pam3CSK4 TFA is a toll-like receptor 1/2 (**TLR1/2**) agonist with an EC_{50} of 0.47 ng/mL for human TLR1/2.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-4878691

(3M-852A)

Cat. No.: HY-100176

PF-4878691 (3M-852A) is a potent, orally active, and selective **Toll-like receptor 7 (TLR7)** agonist modelled to dissociate its antiviral and inflammatory activities.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Polygalasaponin F

Cat. No.: HY-N0392

Polygalasaponin F, an oleanane-type triterpenoid saponin extracted from Polygala japonica, decreases the release of the inflammatory cytokine tumor necrosis factor a (TNFa).



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Polyinosinic-polycytidylic acid sodium

(Poly(I:C) sodium)

Cat. No.: HY-135748

Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is a synthetic analog of double-stranded RNA and an agonist of **toll-like receptor 3 (TLR3)** and **retinoic acid inducible gene I (RIG-I)-like receptors** (**RIG-I** and **MDA5**).

Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Poseltinib

(HM71224; LY3337641)

Cat. No.: HY-109010

Poseltinib, an orally active, selective and irreversible **Bruton's tyrosine kinase (BTK)** inhibitor (IC_{50} =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively.



Purity: 98.01%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

Procyanidin B1

Cat. No.: HY-N0795

Procyanidin B1 is a polyphenolic flavonoid isolated from commonly eaten fruits, binds to **TLR4/MD-2** complex, and has anti-inflammatory activity.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Resatorvid

(TAK-242; CLI-095)

Cat. No.: HY-11109

Resatorvid (TAK-242) is a selective **Toll-like receptor 4 (TLR4)** inhibitor. Resatorvid inhibits **NO**, **TNF-R** and **IL-6** production with IC_{50s} of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Resiquimod

(R848; S28463)

Cat. No.: HY-13740

Resiquimod is a Toll-like receptor 7 and 8 (**TLR7/TLR8**) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Robinin

Cat. No.: HY-N1346

Robinin is present in flavonoid fraction of Vigna unguiculata leaf. Robinin inhibits upregulated expression of **TLR2** and **TLR4**. Robinin ameliorates oxidized low density lipoprotein (Ox-LDL) induced inflammatory insult through TLR4/NF-κB pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Schaftoside

Cat. No.: HY-N0703

Schaftoside is a flavonoid found in a variety of Chinese herbal medicines, such as Eleusine indica. Schaftoside inhibits the expression of TLR4 and Myd88. Schaftoside also decreases Drp1 expression and phosphorylation, and reduces mitochondrial fission.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Selgantolimod

(GS-9688)

Cat. No.: HY-109137

Selgantolimod (GS-9688) is an orally active, potent and selective **toll-like receptor 8 (TLR8)** agonist for the treatment of **hepatitis B virus (HBV)** and human immunodeficiency virus (HIV) infection.



Purity: 99.17%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

SM-276001

Cat. No.: HY-123291

SM-276001 is a potent selective **TLR7** agonist that can induce antitumor immune responses. SM-276001 is an orally active **interferon** (**IFN**) inducer.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sparstolonin B

Cat. No.: HY-116213

Sparstolonin B acts as a selective **TLR2** and **TLR4** antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti-**HIV** and anticancer activities.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sulfo-ara-F-NMN

(CZ-48)

Cat. No.: HY-129522

Sulfo-ara-F-NMN (CZ-48) is a mimetic of nicotinamide mononucleotide (NMN). Sulfo-ara-F-NMN acts selectively, activating **SARM1** but inhibiting **CD38** (IC_{50} around 10 μM). Sulfo-ara-F-NMN induces intracellular cyclic ADP-ribose (cADPR) production.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Telratolimod

(MEDI9197; 3M-052)

Cat. No.: HY-109104

Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (**TLR7/8**) agonist, with antitumor activity.



Purity: 99.04%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TH1020

Cat. No.: HY-116961

TH1020 is a potent and selective **toll-like receptor 5 (TLR5)/flagellin complex** antagonist with an IC_{50} of 0.85 μM. TH1020 inhbits flagellin-induced **TLR5** signaling. TH1020 is inactive against TLR2, TLR3, TLR4, TLR7 and TLR8.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TLR4-IN-C34

Cat. No.: HY-107575

TLR4-IN-C34 is an orally active **TLR4** inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TLR7 agonist 2

Cat. No.: HY-103039

TLR7 agonist 2 is a potent and selective **Toll-like Receptor 7** (**TLR7**) agonist with a **LEC** of 0.4 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TLR7/8 agonist 1 dihydrochloride

Cat. No.: HY-103698A

TLR7/8 agonist 1 dihydrochloride is a toll-like receptor **TLR7/TLR8** dual-agonistic imidazoquinoline.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Toll-like receptor modulator

Cat. No.: HY-10018

Toll-like receptor modulator is a modulator of **TLR7/8**, which modulates immune function.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Vesatolimod

(GS-9620)

Cat. No.: HY-15601

Vesatolimod (GS-9620) is a potent, selective and orally active agonist of **Toll-Like Receptor (TLR7)** with an EC_{50} of 291 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg